Using Tramadol to Measure CYP2D6 Metabolism in Critically Ill Adults
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Agullo L, Aguado I, Muriel J, Margarit C, Gomez A, Escorial M Int J Mol Sci. 2023; 24(13).
PMID: 37445931 PMC: 10341655. DOI: 10.3390/ijms241310754.
CYP2D6 pharmacogenetics and phenoconversion in personalized medicine.
Nahid N, Johnson J Expert Opin Drug Metab Toxicol. 2023; 18(11):769-785.
PMID: 36597259 PMC: 9891304. DOI: 10.1080/17425255.2022.2160317.
References
1.
Abdel-Rahman S, Leeder J, Wilson J, Gaedigk A, Gotschall R, Medve R
. Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation. J Clin Pharmacol. 2002; 42(1):24-9.
DOI: 10.1177/0091270002042001002.
View
2.
Frank D, Jaehde U, Fuhr U
. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol. 2007; 63(4):321-33.
DOI: 10.1007/s00228-006-0250-8.
View
3.
Kirwan C, Lee T, Holt D, Grounds R, MacPhee I, Philips B
. Using midazolam to monitor changes in hepatic drug metabolism in critically ill patients. Intensive Care Med. 2009; 35(7):1271-5.
DOI: 10.1007/s00134-009-1430-7.
View
4.
Lin Y, Lockwood G, Graham M, Brian W, Loi C, Dobrinska M
. In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics. 2001; 11(9):781-91.
DOI: 10.1097/00008571-200112000-00006.
View
5.
Kirwan C, MacPhee I, Lee T, Holt D, Philips B
. Acute kidney injury reduces the hepatic metabolism of midazolam in critically ill patients. Intensive Care Med. 2011; 38(1):76-84.
DOI: 10.1007/s00134-011-2360-8.
View